FDA Says Allergan Misleads Public On Eyelash Drug

Law360, New York (September 17, 2009, 2:59 PM EDT) -- The U.S. Food and Drug Administration has told Allergan Inc. that it has made misleading claims and downplayed potential side effects about its drug Latisse, used to lengthen and darken eyelashes.

In a letter sent to the company Sept. 10 and released Wednesday, the FDA told Allergan to immediately stop disseminating the information about Latisse and to respond to the agency on or before Sept. 24.

Heather Katt, a representative of California-based Allergan, said Thursday that the company was working closely with the FDA to address...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.